Skip to main content
SpringerLink
Log in

Brachytherapy for Posterior Uveal Melanomas

  • Living reference work entry
  • First Online:
Albert and Jakobiec's Principles and Practice of Ophthalmology

  • 47 Accesses

Abstract

Since the reports from the Collaborative Ocular Melanoma Study (COMS) trials indicated that there was no difference in melanoma-specific mortality rates between patients treated with plaque brachytherapy and enucleation for medium-sized tumors, brachytherapy has become the mainstay therapeutic modality for treatment-eligible patients. Currently, iodine-125, ruthenium-106, and palladium-103 are the most commonly used radioactive isotopes for brachytherapy. Many investigators are studying whether a lower radiation dose than the COMS recommendation can achieve similar local tumor control rate, with some promising results. Intraoperative fine needle aspiration biopsy is commonly performed in many centers for further histopathologic, cytogenetic, and genomic analyses that provide critical patient prognostic information. Modern pre-insertion plaque planning and intraoperative ultrasound confirmation of plaque position have led to better local tumor control, which exceeds 95% in many experienced centers. Precise dosimetry is essential because local recurrence of the tumor has been identified as a major risk factor for metastatic disease. Radiation retinopathy is now often managed with anti-vascular endothelial growth factor injections before or at the time of clinically significant development of radiation-induced macular edema.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  1. Murray TG, Latiff A, Villegas VM, Gold AS. Aflibercept for radiation maculopathy study: a prospective, randomized clinical study. Ophthalmol Retina. 2019;3(7):561–6. https://doi.org/10.1016/j.oret.2019.02.009.

    Article  PubMed  Google Scholar 

  2. Fallico M, Reibaldi M, Avitabile T, Longo A, Bonfiglio V, Chronopoulos A, et al. Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma. Graefes Arch Clin Exp Ophthalmol. 2019;257(7):1547–54. https://doi.org/10.1007/s00417-019-04347-6.

    Article  CAS  PubMed  Google Scholar 

  3. Finger PT, Chin KJ. Intravitreous ranibizumab (lucentis) for radiation maculopathy. Arch Ophthalmol. 2010;128(2):249–52. https://doi.org/10.1001/archophthalmol.2009.376.

    Article  PubMed  Google Scholar 

  4. Kim IK, Lane AM, Jain P, Awh C, Gragoudas ES. Ranibizumab for the prevention of radiation complications in patients treated with proton beam irradiation for choroidal melanoma. Trans Am Ophthalmol Soc. 2016;114:T2.

    PubMed  PubMed Central  Google Scholar 

  5. Schefler AC, Fuller D, Anand R, Fuller T, Moore C, Munoz J, et al. Randomized trial of monthly versus as-needed intravitreal Ranibizumab for radiation retinopathy-related macular edema: 1-year outcomes. Am J Ophthalmol. 2020;216:165–73. https://doi.org/10.1016/j.ajo.2020.03.045.

    Article  CAS  PubMed  Google Scholar 

  6. Moore RF. Choroidal sarcoma treated by the intraocular insertion of radon seeds. Br J Ophthalmol. 1930;14(4):145–52. https://doi.org/10.1136/bjo.14.4.145.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Stallard HB. Radiotherapy of malignant intra-ocular neoplasms. Br J Ophthalmol. 1948;32(9):618–39. https://doi.org/10.1136/bjo.32.9.618.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Stallard HB. Malignant melanoma of the choroid treated with radioactive applicators. Trans Ophthalmol Soc U K. 1959;79:373–92.

    CAS  PubMed  Google Scholar 

  9. Sealy R, le Roux PL, Rapley F, Hering E, Shackleton D, Sevel D. The treatment of ophthalmic tumours with low-energy sources. Br J Radiol. 1976;49(582):551–4. https://doi.org/10.1259/0007-1285-49-582-551.

    Article  CAS  PubMed  Google Scholar 

  10. Olsen KRMT, Johnson RN. Enucleation and plaque treatment. In: Albert DMJF, editor. Principles and practice of ophthalmology. Philadelphia: W.B. Saunders and Co; 2000. p. 5028–46.

    Google Scholar 

  11. Lommatzsch P, Dietrich B. Survival rate of patients with choroidal melanoma. Ophthalmologica. 1976;173(6):453–62. https://doi.org/10.1159/000307932.

    Article  CAS  PubMed  Google Scholar 

  12. Paul EV, Parnell BL, Fraker M. Prognosis of malignant melanomas of the choroid and ciliary body. Int Ophthalmol Clin. 1962;2(2):387–402.

    Article  Google Scholar 

  13. Zimmerman LE. Changing concepts concerning the malignancy of ocular tumors. Arch Ophthalmol. 1967;78(2):166–73. https://doi.org/10.1001/archopht.1967.00980030168009.

    Article  CAS  PubMed  Google Scholar 

  14. Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells. Br J Ophthalmol. 1978;62(6):420–5. https://doi.org/10.1136/bjo.62.6.420.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Shammas HF, Blodi FC. Prognostic factors in choroidal and ciliary body melanomas. Arch Ophthalmol. 1977;95(1):63–9. https://doi.org/10.1001/archopht.1977.04450010065005.

    Article  CAS  PubMed  Google Scholar 

  16. Ellsworth R. The treatment of malignant melanoma of the uvea. Trans Aust Coll Ophthalmol. 1971;3:57–60.

    CAS  PubMed  Google Scholar 

  17. Gass JD. Comparison of prognosis after enucleation vs cobalt 60 irradiation of melanomas. Arch Ophthalmol. 1985;103(7):916–23.

    Article  CAS  Google Scholar 

  18. Augsburger JJ, Gamel JW, Sardi VF, Greenberg RA, Shields JA, Brady LW. Enucleation vs cobalt plaque radiotherapy for malignant melanomas of the choroid and ciliary body. Arch Ophthalmol. 1986;104(5):655–61. https://doi.org/10.1001/archopht.1986.01050170045019.

    Article  CAS  PubMed  Google Scholar 

  19. Adams KS, Abramson DH, Ellsworth RM, Haik BG, Bedford M, Packer S, et al. Cobalt plaque versus enucleation for uveal melanoma: comparison of survival rates. Br J Ophthalmol. 1988;72(7):494–7. https://doi.org/10.1136/bjo.72.7.494.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Karlsson UL, Augsburger JJ, Shields JA, Markoe AM, Brady LW, Woodleigh R. Recurrence of posterior uveal melanoma after 60Co episcleral plaque therapy. Ophthalmology. 1989;96(3):382–8.

    Article  CAS  Google Scholar 

  21. Factors predictive of growth and treatment of small choroidal melanoma: COMS Report No. 5. The Collaborative Ocular Melanoma Study Group. Arch Ophthalmol. 1997;115(12):1537–44. https://doi.org/10.1001/archopht.1997.01100160707007.

  22. Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II: characteristics of patients enrolled and not enrolled. COMS report no. 17. Arch Ophthalmol. 2001;119(7):951–65. https://doi.org/10.1001/archopht.119.7.951.

    Article  CAS  PubMed  Google Scholar 

  23. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma II: initial mortality findings. COMS report no. 10. Am J Ophthalmol. 1998;125(6):779–96. https://doi.org/10.1016/s0002-9394(98)00039-7.

  24. Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS report no. 18. Arch Ophthalmol. 2001;119(7):969–82. https://doi.org/10.1001/archopht.119.7.969.

    Article  CAS  PubMed  Google Scholar 

  25. Sobrin L, Schiffman JC, Markoe AM, Murray TG. Outcomes of iodine 125 plaque radiotherapy after initial observation of suspected small choroidal melanomas: a pilot study. Ophthalmology. 2005;112(10):1777–83. https://doi.org/10.1016/j.ophtha.2005.05.003.

    Article  PubMed  Google Scholar 

  26. Shields CL, Naseripour M, Cater J, Shields JA, Demirci H, Youseff A, et al. Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients. Ophthalmology. 2002;109(10):1838–49.

    Article  Google Scholar 

  27. Puusaari I, Heikkonen J, Summanen P, Tarkkanen A, Kivela T. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Ophthalmology. 2003;110(11):2223–34. https://doi.org/10.1016/S0161-6420(03)00661-4.

    Article  PubMed  Google Scholar 

  28. Stallard HB. The conservative treatment of retinoblastoma. Highlights Ophthalmol. 1963;6:129–30.

    Google Scholar 

  29. Shields CL, Shields JA, Gunduz K, Freire JE, Mercado G. Radiation therapy for uveal malignant melanoma. Ophthalmic Surg Lasers. 1998;29(5):397–409.

    Article  CAS  Google Scholar 

  30. Quivey J, Takamiya R, Char D. Uveal melanoma. In: Leibel SA, Phillips TL, editors. Textbook of radiation oncology. 2nd ed. Philadelphia: Saunders; 2004. p. 1443–661.

    Google Scholar 

  31. Straatsma BR, Fine SL, Earle JD, Hawkins BS, Diener-West M, McLaughlin JA. Enucleation versus plaque irradiation for choroidal melanoma. Ophthalmology. 1988;95(7):1000–4.

    Article  CAS  Google Scholar 

  32. Earle J, Kline RW, Robertson DM. Selection of iodine 125 for the collaborative ocular melanoma study. Arch Ophthalmol. 1987;105(6):763–4. https://doi.org/10.1001/archopht.1987.01060060049030.

    Article  CAS  PubMed  Google Scholar 

  33. Finger PT, Berson A, Ng T, Szechter A. Palladium-103 plaque radiotherapy for choroidal melanoma: an 11-year study. Int J Radiat Oncol Biol Phys. 2002;54(5):1438–45.

    Article  Google Scholar 

  34. Nag S, Quivey JM, Earle JD, Followill D, Fontanesi J, Finger PT, et al. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys. 2003;56(2):544–55.

    Article  Google Scholar 

  35. Goodman DF, Char DH, Crawford JB, Stone RD, Castro JR. Uveal melanoma necrosis after helium ion therapy. Am J Ophthalmol. 1986;101(6):643–5. https://doi.org/10.1016/0002-9394(86)90762-2.

    Article  CAS  PubMed  Google Scholar 

  36. Luxton G, Astrahan MA, Liggett PE, Neblett DL, Cohen DM, Petrovich Z. Dosimetric calculations and measurements of gold plaque ophthalmic irradiators using iridium-192 and iodine-125 seeds. Int J Radiat Oncol Biol Phys. 1988;15(1):167–76.

    Article  CAS  Google Scholar 

  37. Ling CC, Chen GT, Boothby JW, Weaver K, Stuart A, Barnett C, et al. Computer assisted treatment planning for 125I ophthalmic plaque radiotherapy. Int J Radiat Oncol Biol Phys. 1989;17(2):405–10.

    Article  CAS  Google Scholar 

  38. Luxton G, Astrahan MA, Findley DO, Petrovich Z. Measurement of dose rate from exposure-calibrated 125I seeds. Int J Radiat Oncol Biol Phys. 1990;18(5):1199–207.

    Article  CAS  Google Scholar 

  39. Williamson JF. Monte Carlo evaluation of specific dose constants in water for 125I seeds. Med Phys. 1988;15(5):686–94. https://doi.org/10.1118/1.596181.

    Article  CAS  PubMed  Google Scholar 

  40. Astrahan MA, Luxton G, Pu Q, Petrovich Z. Conformal episcleral plaque therapy. Int J Radiat Oncol Biol Phys. 1997;39(2):505–19.

    Article  CAS  Google Scholar 

  41. Dean MK, Studenski MT, Paez-Escamilla MA, Walter SD, Kwon D, Markoe AM, et al. Dosimetric comparison of circular eye physics and collaborative ocular melanoma study plaques to treat uveal melanoma. Brachytherapy. 2019;18(3):404–10. https://doi.org/10.1016/j.brachy.2019.01.005.

    Article  PubMed  Google Scholar 

  42. Gunduz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol. 1999;117(5):609–14. https://doi.org/10.1001/archopht.117.5.609.

    Article  CAS  PubMed  Google Scholar 

  43. Quivey JM, Augsburger J, Snelling L, Brady LW. 125I plaque therapy for uveal melanoma. Analysis of the impact of time and dose factors on local control. Cancer. 1996;77(11):2356–62. https://doi.org/10.1002/(SICI)1097-0142(19960601)77:11<2356::AID-CNCR26>3.0.CO;2-V.

    Article  CAS  PubMed  Google Scholar 

  44. Murray TG, Markoe AM, Gold AS, Ehlies F, Bermudez E, Wildner A, et al. Long-term followup comparing two treatment dosing strategies of (125) I plaque radiotherapy in the management of small/medium posterior uveal melanoma. J Ophthalmol. 2013;2013:517032. https://doi.org/10.1155/2013/517032.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Naseripour M, Jaberi R, Sedaghat A, Azma Z, Nojomi M, Falavarjani KG, et al. Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate. J Contemp Brachytherapy. 2016;8(1):66–73. https://doi.org/10.5114/jcb.2016.57818.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Jampol LM, Moy CS, Murray TG, Reynolds SM, Albert DM, Schachat AP, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology. 2002;109(12):2197–206.

    Article  Google Scholar 

  47. American Brachytherapy Society – Ophthalmic Oncology Task Force. Electronic address pec, Committee AO. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13(1):1–14. https://doi.org/10.1016/j.brachy.2013.11.008.

    Article  Google Scholar 

  48. Berry JL, Dandapani SV, Stevanovic M, Lee TC, Astrahan M, Murphree AL, et al. Outcomes of choroidal melanomas treated with eye physics: a 20-year review. JAMA Ophthalmol. 2013;131(11):1435–42. https://doi.org/10.1001/jamaophthalmol.2013.4422.

    Article  PubMed  Google Scholar 

  49. Kim RS, Chevez-Barrios P, Bretana ME, Wong TP, Teh BS, Schefler AC. Histopathologic analysis of transvitreal fine needle aspiration biopsy needle tracts for uveal melanoma. Am J Ophthalmol. 2017;174:9–16. https://doi.org/10.1016/j.ajo.2016.10.019.

    Article  PubMed  Google Scholar 

  50. Shields CL, Ganguly A, Materin MA, Teixeira L, Mashayekhi A, Swanson LA, et al. Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases. Trans Am Ophthalmol Soc. 2007;105:43–52; discussion -3.

    PubMed  PubMed Central  Google Scholar 

  51. Singh AD, Medina CA, Singh N, Aronow ME, Biscotti CV, Triozzi PL. Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. Br J Ophthalmol. 2016;100(4):456–62. https://doi.org/10.1136/bjophthalmol-2015-306921.

    Article  PubMed  Google Scholar 

  52. Kim RS, Chevez-Barrios P, Divatia M, Bretana ME, Teh B, Schefler AC. Yield, techniques, and complications of transvitreal and transscleral biopsies in small uveal melanoma. JAMA Ophthalmol. 2018;136(5):482–8. https://doi.org/10.1001/jamaophthalmol.2018.0561.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Robertson DM, Fuller DG, Anderson RE. A technique for accurate placement of episcleral iodine-125 plaques. Am J Ophthalmol. 1987;103(1):63–5. https://doi.org/10.1016/s0002-9394(14)74171-6.

    Article  CAS  PubMed  Google Scholar 

  54. Tabandeh H, Chaudhry NA, Murray TG, Ehlies F, Hughes R, Scott IU, et al. Intraoperative echographic localization of iodine-125 episcleral plaque for brachytherapy of choroidal melanoma. Am J Ophthalmol. 2000;129(2):199–204. https://doi.org/10.1016/s0002-9394(99)00315-3.

    Article  CAS  PubMed  Google Scholar 

  55. Harbour JW, Murray TG, Byrne SF, Hughes JR, Gendron EK, Ehlies FJ, et al. Intraoperative echographic localization of iodine 125 episcleral radioactive plaques for posterior uveal melanoma. Retina. 1996;16(2):129–34.

    Article  CAS  Google Scholar 

  56. Aziz HA, Al Zahrani YA, Bena J, Lorek B, Wilkinson A, Suh J, et al. Episcleral brachytherapy of uveal melanoma: role of intraoperative echographic confirmation. Br J Ophthalmol. 2017;101(6):747–51. https://doi.org/10.1136/bjophthalmol-2016-309153.

    Article  PubMed  Google Scholar 

  57. Foerster MH, Bornfeld N, Schulz U, Wessing A, Meyer-Schwickerath G. Complications of local beta radiation of uveal melanomas. Graefes Arch Clin Exp Ophthalmol. 1986;224(4):336–40.

    Article  CAS  Google Scholar 

  58. Hui JI, Murray TG. Radioactive plaque therapy. Int Ophthalmol Clin. 2006;46(1):51–68.

    Article  Google Scholar 

  59. Char DH, Quivey JM, Castro JR, Kroll S, Phillips T. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology. 1993;100(10):1547–54.

    Article  CAS  Google Scholar 

  60. Collaborative Ocular Melanoma Study G. Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine 125 brachytherapy in the collaborative ocular melanoma study: COMS report no. 27. Ophthalmology. 2007;114(7):1363–71. https://doi.org/10.1016/j.ophtha.2006.10.039.

    Article  Google Scholar 

  61. Shah NV, Houston SK, Markoe AM, Feuer W, Murray TG. Early SD-OCT diagnosis followed by prompt treatment of radiation maculopathy using intravitreal bevacizumab maintains functional visual acuity. Clin Ophthalmol. 2012;6:1739–48. https://doi.org/10.2147/OPTH.S34949.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Horgan N, Shields CL, Mashayekhi A, Teixeira LF, Materin MA, Shields JA. Early macular morphological changes following plaque radiotherapy for uveal melanoma. Retina. 2008;28(2):263–73. https://doi.org/10.1097/IAE.0b013e31814b1b75.

    Article  PubMed  Google Scholar 

  63. Mashayekhi A, Rojanaporn D, Al-Dahmash S, Shields CL, Shields JA. Monthly intravitreal bevacizumab for macular edema after iodine-125 plaque radiotherapy of uveal melanoma. Eur J Ophthalmol. 2014;24(2):228–34. https://doi.org/10.5301/ejo.5000352.

    Article  PubMed  Google Scholar 

  64. Bianciotto C, Shields CL, Pirondini C, Mashayekhi A, Furuta M, Shields JA. Proliferative radiation retinopathy after plaque radiotherapy for uveal melanoma. Ophthalmology. 2010;117(5):1005–12. https://doi.org/10.1016/j.ophtha.2009.10.015.

    Article  PubMed  Google Scholar 

  65. Gragoudas ES, Lane AM, Regan S, Li W, Judge HE, Munzenrider JE, et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol. 2000;118(6):773–8. https://doi.org/10.1001/archopht.118.6.773.

    Article  CAS  PubMed  Google Scholar 

  66. De Potter P, Shields CL, Shields JA, Cater JR, Brady LW. Plaque radiotherapy for juxtapapillary choroidal melanoma. Visual acuity and survival outcome. Arch Ophthalmol. 1996;114(11):1357–65. https://doi.org/10.1001/archopht.1996.01100140557006.

    Article  PubMed  Google Scholar 

  67. Shields CL, Cater J, Shields JA, Chao A, Krema H, Materin M, et al. Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol. 2002;120(7):933–40. https://doi.org/10.1001/archopht.120.7.933.

    Article  PubMed  Google Scholar 

  68. Augsburger JJ, Roth SE, Magargal LE, Shields JA. Panretinal photocoagulation for radiation-induced ocular ischemia. Ophthalmic Surg. 1987;18(8):589–93.

    CAS  PubMed  Google Scholar 

  69. Stacey AW, Demirci H. Serial Intravitreal Bevacizumab injections slow the progression of radiation maculopathy following Iodine-125 plaque radiotherapy. Open Ophthalmol J. 2016;10:103–10. https://doi.org/10.2174/1874364101610010103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Khan MA, Mashayekhi A, Shields JA, Shields CL. Intravitreal Aflibercept as rescue therapy for post-radiation cystoid macular edema resistant to intravitreal Bevacizumab: outcomes at 1 year. Ocul Oncol Pathol. 2017;3(4):313–9. https://doi.org/10.1159/000452163.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Shah SU, Shields CL, Bianciotto CG, Iturralde J, Al-Dahmash SA, Say EAT, et al. Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma. Ophthalmology. 2014;121(1):269–75. https://doi.org/10.1016/j.ophtha.2013.08.039.

    Article  PubMed  Google Scholar 

  72. Gupta A, Muecke JS. Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin). Retina. 2008;28(7):964–8. https://doi.org/10.1097/IAE.0b013e3181706302.

    Article  PubMed  Google Scholar 

  73. Finger PT, Chin KJ, Semenova EA. Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study. Eur J Ophthalmol. 2016;26(1):60–6. https://doi.org/10.5301/ejo.5000670.

    Article  PubMed  Google Scholar 

  74. Yeung SN, Paton KE, Waite C, Maberley DA. Intravitreal bevacizumab for iris neovascularization following proton beam irradiation for choroidal melanoma. Can J Ophthalmol. 2010;45(3):269–73. https://doi.org/10.3129/i09-259.

    Article  PubMed  Google Scholar 

  75. Douat J, Auriol S, Mahieu-Durringer L, Ancele E, Pagot-Mathis V, Mathis A. Intravitreal bevacizumab for treatment of neovascular glaucoma. Report of 20 cases. J Fr Ophtalmol. 2009;32(9):652–63. https://doi.org/10.1016/j.jfo.2009.10.001.

    Article  CAS  PubMed  Google Scholar 

  76. Nagendran ST, Finger PT. Anti-VEGF intravitreal bevacizumab for radiation-associated neovascular glaucoma. Ophthalmic Surg Lasers Imaging Retina. 2015;46(2):201–7. https://doi.org/10.3928/23258160-20150213-08.

    Article  PubMed  Google Scholar 

  77. Straatsma BR, Diener-West M, Caldwell R, Engstrom RE, Collaborative Ocular Melanoma Study G. Mortality after deferral of treatment or no treatment for choroidal melanoma. Am J Ophthalmol. 2003;136(1):47–54. https://doi.org/10.1016/s0002-9394(02)02270-5.

    Article  PubMed  Google Scholar 

  78. Ophthalmic Oncology Task F. Local recurrence significantly increases the risk of metastatic uveal melanoma. Ophthalmology. 2016;123(1):86–91. https://doi.org/10.1016/j.ophtha.2015.09.014.

    Article  Google Scholar 

  79. Tann AW, Teh BS, Scarboro SB, Lewis GD, Bretana ME, Croft PC, et al. Early outcomes of uveal melanoma treated with intraoperative ultrasound guided brachytherapy using custom built plaques. Pract Radiat Oncol. 2017;7(4):e275–e82. https://doi.org/10.1016/j.prro.2017.01.002.

    Article  PubMed  Google Scholar 

  80. Mruthyunjaya P, Seider MI, Stinnett S, Schefler A, Ocular Oncology Study C. Association between tumor regression rate and gene expression profile after iodine 125 plaque radiotherapy for uveal melanoma. Ophthalmology. 2017;124(10):1532–9. https://doi.org/10.1016/j.ophtha.2017.04.013.

    Article  PubMed  Google Scholar 

  81. Finger PT, Tena LB, Semenova E, Aridgides P, Choi WH. Extrascleral extension of choroidal melanoma: post-enucleation high-dose-rate interstitial brachytherapy of the orbit. Brachytherapy. 2014;13(3):275–80. https://doi.org/10.1016/j.brachy.2013.09.002.

    Article  PubMed  Google Scholar 

  82. Quivey JM, Char DH, Phillips TL, Weaver KA, Castro JR, Kroll SM. High intensity 125-iodine (125I) plaque treatment of uveal melanoma. Int J Radiat Oncol Biol Phys. 1993;26(4):613–8.

    Article  CAS  Google Scholar 

  83. Fontanesi J, Meyer D, Xu S, Tai D. Treatment of choroidal melanoma with I-125 plaque. Int J Radiat Oncol Biol Phys. 1993;26(4):619–23.

    Article  CAS  Google Scholar 

  84. Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF, et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology. 2001;108(2):348–66.

    Article  CAS  Google Scholar 

  85. Shields CL, Shields JA, Cater J, Gunduz K, Miyamoto C, Micaily B, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol. 2000;118(9):1219–28. https://doi.org/10.1001/archopht.118.9.1219.

    Article  CAS  PubMed  Google Scholar 

  86. Melia M, Moy CS, Reynolds SM, Hayman JA, Murray TG, Hovland KR, et al. Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the collaborative ocular melanoma study: COMS QOLS report no. 3. Arch Ophthalmol. 2006;124(2):226–38. https://doi.org/10.1001/archopht.124.2.226.

    Article  PubMed  Google Scholar 

  87. Brandberg Y, Kock E, Oskar K, af Trampe E, Seregard S. Psychological reactions and quality of life in patients with posterior uveal melanoma treated with ruthenium plaque therapy or enucleation: a one year follow-up study. Eye (Lond). 2000;14(Pt 6):839–46. https://doi.org/10.1038/eye.2000.233.

    Article  CAS  Google Scholar 

  88. Blanco-Rivera C, Capeans-Tome C, Otero-Cepeda XL. Quality of life in patients with choroidal melanoma. Arch Soc Esp Oftalmol. 2008;83(5):301–6.

    Article  CAS  Google Scholar 

  89. Finger PT. Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol. 2000;84(9):1068–70. https://doi.org/10.1136/bjo.84.9.1068.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Wilson MW, Hungerford JL. Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. Ophthalmology. 1999;106(8):1579–87. https://doi.org/10.1016/S0161-6420(99)90456-6.

    Article  CAS  PubMed  Google Scholar 

  91. Lommatzsch PK, Werschnik C, Schuster E. Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 2000;238(2):129–37.

    Article  CAS  Google Scholar 

  92. Rouberol F, Roy P, Kodjikian L, Gerard JP, Jean-Louis B, Grange JD. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years’ experience with beta-rays). Am J Ophthalmol. 2004;137(5):893–900. https://doi.org/10.1016/j.ajo.2003.12.032.

    Article  CAS  PubMed  Google Scholar 

  93. Damato B, Patel I, Campbell IR, Mayles HM, Errington RD. Local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys. 2005;63(2):385–91. https://doi.org/10.1016/j.ijrobp.2005.02.017.

    Article  PubMed  Google Scholar 

  94. Bergman L, Nilsson B, Lundell G, Lundell M, Seregard S. Ruthenium brachytherapy for uveal melanoma, 1979–2003: survival and functional outcomes in the Swedish population. Ophthalmology. 2005;112(5):834–40. https://doi.org/10.1016/j.ophtha.2004.11.038.

    Article  PubMed  Google Scholar 

  95. Collaborative Ocular Melanoma Study G. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report no. 28. Arch Ophthalmol. 2006;124(12):1684–93. https://doi.org/10.1001/archopht.124.12.1684.

    Article  Google Scholar 

  96. Mortality in patients with small choroidal melanoma. COMS report no. 4. The collaborative ocular melanoma study group. Arch Ophthalmol. 1997;115(7):886–93.

    Google Scholar 

  97. Augsburger JJ. Is observation really appropriate for small choroidal melanomas. Trans Am Ophthalmol Soc. 1993;91:147–68; discussion 69–75.

    CAS  PubMed  PubMed Central  Google Scholar 

  98. Robertson DM. Changing concepts in the management of choroidal melanoma. Am J Ophthalmol. 2003;136(1):161–70. https://doi.org/10.1016/s0002-9394(03)00265-4.

    Article  PubMed  Google Scholar 

  99. Shields JA, Shields CL. Management of posterior uveal melanoma: past, present, and future: the 2014 Charles L Schepens lecture. Ophthalmology. 2015;122(2):414–28. https://doi.org/10.1016/j.ophtha.2014.08.046.

    Article  PubMed  Google Scholar 

  100. Damato B. Progress in the management of patients with uveal melanoma. The 2012 Ashton lecture. Eye (Lond). 2012;26(9):1157–72. https://doi.org/10.1038/eye.2012.126.

    Article  CAS  Google Scholar 

  101. Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology. 2000;107(8):1443–9.

    Article  CAS  Google Scholar 

  102. Shields CL, Furuta M, Berman EL, Zahler JD, Hoberman DM, Dinh DH, et al. Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases. Arch Ophthalmol. 2009;127(8):981–7. https://doi.org/10.1001/archophthalmol.2009.151.

    Article  PubMed  Google Scholar 

  103. Butler P, Char DH, Zarbin M, Kroll S. Natural history of indeterminate pigmented choroidal tumors. Ophthalmology. 1994;101(4):710–6; discussion 7.

    Article  CAS  Google Scholar 

  104. Verschueren KM, Creutzberg CL, Schalij-Delfos NE, Ketelaars M, Klijsen FL, Haeseker BI, et al. Long-term outcomes of eye-conserving treatment with ruthenium(106) brachytherapy for choroidal melanoma. Radiother Oncol. 2010;95(3):332–8. https://doi.org/10.1016/j.radonc.2010.03.023.

    Article  PubMed  Google Scholar 

  105. Perri P, Fiorica F, D’Angelo S, Lamberti G, Parmeggiani F, Martini A, et al. Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: a mono-institutional experience. Eur Rev Med Pharmacol Sci. 2012;16(14):1919–24.

    CAS  PubMed  Google Scholar 

  106. Semenova E, Finger PT. Palladium-103 radiation therapy for small choroidal melanoma. Ophthalmology. 2013;120(11):2353–7. https://doi.org/10.1016/j.ophtha.2013.04.017.

    Article  PubMed  Google Scholar 

  107. Kines RC, Varsavsky I, Choudhary S, Bhattacharya D, Spring S, McLaughlin R, et al. An infrared dye-conjugated virus-like particle for the treatment of primary uveal melanoma. Mol Cancer Ther. 2018;17(2):565–74. https://doi.org/10.1158/1535-7163.MCT-17-0953.

    Article  CAS  PubMed  Google Scholar 

  108. Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). 2017;31(2):241–57. https://doi.org/10.1038/eye.2016.275.

    Article  CAS  Google Scholar 

  109. Hawkins BS. The collaborative ocular melanoma study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol. 2004;138(6):936–51. https://doi.org/10.1016/j.ajo.2004.07.006.

    Article  PubMed  Google Scholar 

  110. Caminal JM, Ribes J, Cleries R, Ibanez N, Arias L, Piulats JM, et al. Relative survival of patients with uveal melanoma managed in a single center. Melanoma Res. 2012;22(3):271–7. https://doi.org/10.1097/CMR.0b013e328353ef30.

    Article  PubMed  Google Scholar 

  111. Cho Y, Chang JS, Yoon JS, Lee SC, Kim YB, Kim JH, et al. Ruthenium-106 brachytherapy with or without additional local therapy shows Favorable outcome for variable-sized choroidal melanomas in Korean patients. Cancer Res Treat. 2018;50(1):138–47. https://doi.org/10.4143/crt.2016.391.

    Article  CAS  PubMed  Google Scholar 

  112. McCannel TA, Kamrava M, Demanes J, Lamb J, Bartlett JD, Almanzor R, et al. 23-mm iodine-125 plaque for uveal melanoma: benefit of vitrectomy and silicone oil on visual acuity. Graefes Arch Clin Exp Ophthalmol. 2016;254(12):2461–7. https://doi.org/10.1007/s00417-016-3485-9.

    Article  PubMed  Google Scholar 

  113. Oliver SC, Leu MY, DeMarco JJ, Chow PE, Lee SP, McCannel TA. Attenuation of iodine 125 radiation with vitreous substitutes in the treatment of uveal melanoma. Arch Ophthalmol. 2010;128(7):888–93. https://doi.org/10.1001/archophthalmol.2010.117.

    Article  PubMed  Google Scholar 

  114. Le BHA, Kim JW, Deng H, Rayess N, Jennelle RL, Zhou SY, et al. Outcomes of choroidal melanomas treated with eye physics plaques: a 25-year review. Brachytherapy. 2018;17(6):981–9. https://doi.org/10.1016/j.brachy.2018.07.002.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Sanchez-Tabernero S, Garcia-Alvarez C, Munoz-Moreno MF, Diezhandino P, Alonso-Martinez P, de Frutos-Baraja JM, et al. Pattern of local recurrence after I-125 episcleral brachytherapy for uveal melanoma in a Spanish referral ocular oncology unit. Am J Ophthalmol. 2017;180:39–45. https://doi.org/10.1016/j.ajo.2017.05.019.

    Article  PubMed  Google Scholar 

  116. Puusaari I, Damato B, Kivela T. Transscleral local resection versus iodine brachytherapy for uveal melanomas that are large because of tumour height. Graefes Arch Clin Exp Ophthalmol. 2007;245(4):522–33. https://doi.org/10.1007/s00417-006-0461-9.

    Article  PubMed  Google Scholar 

  117. Stack R, Elder M, Abdelaal A, Hidajat R, Clemett R. New Zealand experience of I125 brachytherapy for choroidal melanoma. Clin Exp Ophthalmol. 2005;33(5):490–4. https://doi.org/10.1111/j.1442-9071.2005.01067.x.

    Article  PubMed  Google Scholar 

  118. Correa R, Pera J, Gomez J, Polo A, Gutierrez C, Caminal JM, et al. (125)I episcleral plaque brachytherapy in the treatment of choroidal melanoma: a single-institution experience in Spain. Brachytherapy. 2009;8(3):290–6. https://doi.org/10.1016/j.brachy.2009.03.189.

    Article  PubMed  Google Scholar 

  119. Sia S, Harper C, McAllister I, Perry A. Iodine-I25 episcleral plaque therapy in uveal melanoma. Clin Exp Ophthalmol. 2000;28(6):409–13.

    Article  CAS  Google Scholar 

  120. Jensen AW, Petersen IA, Kline RW, Stafford SL, Schomberg PJ, Robertson DM. Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma. Int J Radiat Oncol Biol Phys. 2005;63(1):101–8. https://doi.org/10.1016/j.ijrobp.2005.01.022.

    Article  PubMed  Google Scholar 

  121. Karlovits B, Trombetta MG, Verstraeten T, Johnson M, Wong M, Karlovits S. Local control and visual acuity following treatment of medium-sized ocular melanoma using a contact eye plaque: a single surgeon experience. Brachytherapy. 2011;10(3):228–31. https://doi.org/10.1016/j.brachy.2010.09.003.

    Article  PubMed  Google Scholar 

  122. Tarmann L, Wackernagel W, Avian A, Mayer C, Schneider M, Winkler P, et al. Ruthenium-106 plaque brachytherapy for uveal melanoma. Br J Ophthalmol. 2015;99(12):1644–9. https://doi.org/10.1136/bjophthalmol-2015-306666.

    Article  PubMed  Google Scholar 

  123. Rospond-Kubiak I, Wroblewska-Zierhoffer M, Twardosz-Pawlik H, Kociecki J. Ruthenium brachytherapy for uveal melanoma - single institution experience. J Contemp Brachytherapy. 2017;9(6):548–52. https://doi.org/10.5114/jcb.2017.72606.

    Article  PubMed  PubMed Central  Google Scholar 

  124. Barker CA, Francis JH, Cohen GN, Marr BP, Wolden SL, McCormick B, et al. (106)Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence. Brachytherapy. 2014;13(6):584–90. https://doi.org/10.1016/j.brachy.2014.04.002.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Retina Consultants of Texas, Houston, TX, USA

    Amy C. Schefler & Ryan S. Kim

  2. Blanton Eye Institute, Houston Methodist Hospital, Weill Cornell Medical College, Houston, TX, USA

    Amy C. Schefler

  3. McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA

    Ryan S. Kim

Authors
  1. Amy C. Schefler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryan S. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amy C. Schefler .

Editor information

Editors and Affiliations

  1. Department of Ophthalmology, Oregon Health & Science University Department of Ophthalmology, Portland, OR, USA

    Daniel Albert

  2. Massachusetts Eye and Ear, Boston, MA, USA

    Joan Miller

  3. Department of Ophthalmology, University of Illinois at Chicago Department of Ophthalmology, Chicago, IL, USA

    Dimitri Azar

  4. Department of Ophthalmology, Harvard Medical School, Boston, MA, USA

    Lucy H. Young

Section Editor information

  1. No affiliation provided

    Joan Marie O’Brien

  2. No affiliation provided

    Evangelos S. Gragoudas

  3. No affiliation provided

    Dan Gombos

  4. No affiliation provided

    Mary Aronow

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Schefler, A.C., Kim, R.S. (2021). Brachytherapy for Posterior Uveal Melanomas. In: Albert, D., Miller, J., Azar, D., Young, L.H. (eds) Albert and Jakobiec's Principles and Practice of Ophthalmology. Springer, Cham. https://doi.org/10.1007/978-3-319-90495-5_250-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-90495-5_250-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-90495-5

  • Online ISBN: 978-3-319-90495-5

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation